|
6 Companies |
|
4 Products |
|
4 Products |
|
5 Mechanisms of Action |
|
0 Trials |
|
27 News |
|
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change: Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Oct 9, 2018
P3, N=224, Completed, Sponsor: J. Fernando Arevalo, MD FACS
Active, not recruiting --> Completed | N=374 --> 224
- || Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: (clinicaltrials.gov) - Jul 27, 2018
P2/3, N=25, Completed, Sponsor: King's College Hospital NHS Trust
Active, not recruiting --> Completed | N=374 --> 224 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Mar 6, 2018
P3, N=374, Active, not recruiting, Sponsor: J. Fernando Arevalo, MD FACS
Active, not recruiting --> Completed Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Jul 2017 --> Jul 2018
- Eylea (aflibercept intravitreal) / Bayer, Regeneron
Trial completion: Aflibercept Injection for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Jan 17, 2017
P2, N=12, Completed, Sponsor: University of Oklahoma
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Jul 2017 --> Jul 2018 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date: Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Aug 30, 2016
P3, N=374, Active, not recruiting, Sponsor: J. Fernando Arevalo, MD FACS
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Jul 2017
- Avastin (bevacizumab) / Roche
Trial primary completion date: Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Feb 23, 2016
P3, N=374, Active, not recruiting, Sponsor: J. Fernando Arevalo, MD FACS
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Jul 2015 --> Jul 2016
- | Avastin (bevacizumab) / Roche
Enrollment closed: Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Sep 1, 2015
P3, N=374, Active, not recruiting, Sponsor: J. Fernando Arevalo, MD FACS
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: (clinicaltrials.gov) - Aug 17, 2015
P2/3, N=24, Active, not recruiting, Sponsor: King's College Hospital NHS Trust
Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> Dec 2015
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: (clinicaltrials.gov) - Jan 28, 2015
P2/3, N=24, Active, not recruiting, Sponsor: King's College Hospital NHS Trust
Trial primary completion date: May 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Enrollment open, Trial primary completion date: Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Oct 4, 2014
P3, N=374, Recruiting, Sponsor: J. Fernando Arevalo, MD FACS
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2014 --> Jul 2015
- sevoflurane / Generic mfg.
Surgery: Different Hemostasis According to the Anesthetic Agents (clinicaltrials.gov) - May 26, 2014
P=N/A, N=66, Completed, Sponsor: Seoul National University Bundang Hospital
- sevoflurane / Generic mfg.
Trial completion, Surgery: Different Hemostasis According to the Anesthetic Agents (clinicaltrials.gov) - May 26, 2014
P=N/A, N=66, Completed, Sponsor: Seoul National University Bundang Hospital
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2014 --> Jul 2015 Not yet recruiting --> Completed
- Macugen (pegaptanib) / Bausch Health
Trial withdrawal: A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Mar 3, 2014
P3, N=0, Withdrawn, Sponsor: Greater Houston Retina Research
Not yet recruiting --> Completed Recruiting --> Withdrawn
- Macugen (pegaptanib) / Bausch Health
Enrollment change: A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Mar 3, 2014
P3, N=0, Withdrawn, Sponsor: Greater Houston Retina Research
Recruiting --> Withdrawn N=20 --> 0
- Eylea (aflibercept intravitreal) / Bayer, Regeneron
Enrollment closed: Aflibercept Injection for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Dec 18, 2013
P2, N=12, Active, not recruiting, Sponsor: University of Oklahoma
N=20 --> 0 Not yet recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment change, Surgery: Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Dec 3, 2013
P4, N=66, Completed, Sponsor: Nihon University
Not yet recruiting --> Active, not recruiting N=120 --> 66
- Avastin (bevacizumab) / Roche
Trial completion, Surgery: Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Dec 3, 2013
P4, N=66, Completed, Sponsor: Nihon University
N=120 --> 66 Recruiting --> Completed
- || Avastin (bevacizumab) / Roche
New P3 trial: Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Nov 4, 2013
P3, N=374, Not yet recruiting, Sponsor: J. Fernando Arevalo, MD FACS
- | Avastin (bevacizumab) / Roche
New P4 trial, Surgery: Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - May 13, 2013
P4, N=66, Completed, Sponsor: Nihon University
- Avastin (bevacizumab) / Roche
Trial completion: Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Apr 24, 2013
P4, N=18, Completed, Sponsor: Khon Kaen University
Recruiting --> Completed Recruiting --> Completed
- Eylea (aflibercept intravitreal) / Bayer, Regeneron
New P2 trial: Aflibercept Injection for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Mar 4, 2013
P2, N=12, Active, not recruiting, Sponsor: University of Oklahoma
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) (clinicaltrials.gov) - Jan 10, 2013
P2/3, N=261, Completed, Sponsor: Diabetic Retinopathy Clinical Research Network
Recruiting --> Completed N=136 --> 261
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) (clinicaltrials.gov) - Jan 10, 2013
P2/3, N=261, Completed, Sponsor: Diabetic Retinopathy Clinical Research Network
N=136 --> 261 Active, not recruiting --> Completed
- Enrollment change: Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=61, Completed, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed N=30 --> 61
- Trial completion: Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=61, Completed, Sponsor: National Taiwan University Hospital
N=30 --> 61 Recruiting --> Completed
- Avastin (bevacizumab) / Roche
New P4 trial: Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Nov 7, 2012
P4, N=18, Completed, Sponsor: Khon Kaen University
- Macugen (pegaptanib) / Bausch Health
New P3 trial: A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy (clinicaltrials.gov) - Apr 30, 2012
P3, N=0, Withdrawn, Sponsor: Greater Houston Retina Research
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: (clinicaltrials.gov) - Aug 15, 2011
P2/3, N=24, Recruiting, Sponsor: King's College Hospital NHS Trust
Recruiting --> Completed Not yet recruiting --> Recruiting